Current Status and Unusual Mechanism of Multiresistance in Mycobacterium tuberculosis

A. Chakraborty
{"title":"Current Status and Unusual Mechanism of Multiresistance in Mycobacterium tuberculosis","authors":"A. Chakraborty","doi":"10.4172/2157-7420.1000328","DOIUrl":null,"url":null,"abstract":"TB is a deadly disease and MDR-TB is spreading even DOTS drug regime has rigorously maintained with at least ten new drugs like isoniazid, capreomycin, dapsone, linezolid, pyrazinamide, ethambutol and Beda quinolone apart from traditional drugs like rifampicin, streptomycin, amikacin and clarithromycin. Rifampicin inhibits RNA polymerase and mutations in rpo gene codons give resistance. Streptomycin inhibits protein synthesis and mutation of ribosomal proteins and rRNA genes give resistance but no strAB or mphA1-9 mdr genes reported in Mycobacterium. Bedaquiline kills M. tuberculosis by inhibition of the membrane-bound F1F0-ATP synthase complex. Ciprofloxacin and ofloxacin were replaced by moxifloxacin that binds to DNA gyrase inhibiting DNA replication and/or transcription and mutations of gyrA at position 90 and 94 and gyrB at position 74, 88 and 91 give resistance. Kanamycin and amikacin inhibit protein synthesis and mutation of rrs gene gives resistance. However, aac2’-Ic type acetylating enzymes have also been suggested for multi-resistance. Ethambutol interferes with the biosynthesis of arabinogalactan in the cell wall and embB gene mutation at position 306 gives resistance. ErmMT methyl transferase adds methyl group to 23S rRNA at A2058 giving resistance to azithromycin and clarithromycin where capreomycin or viomycin peptide antibiotics may be effective drug. Ethionamide is a derivative of isonicotinic acid inhibits mycolic acid synthesis disrupting membrane function. Ethionamide resistance were linked due to mutations in etaA, ethA, ethR and inhA genes. Isoniazid is also a pro-drug and katG gene (S315T) mutation was reported for its resistance. Pyrazinamide after conversion to pyrazinoic acid disrupts membrane function inhibiting ATP synthesis and pncA or rpsA gene mutation likely gives resistance. Cycloserine is a peptidoglycan synthesis inhibitor competing D-Alanine ligase. We find beta-lactamase (BlaC) and penicillin binding protein (penA) as well as well studied emrB and qacB drug efflux proteins by genome wide search. But no 50-500 kb MDR plasmid carrying five or more mdr genes as found in most Enterobacteriaceae, have not sequenced in M. tuberculosis. We conclude that search for Mycobacterium plasmids must be accelerated pointing multi-resistance. Surely, phage therapy and gene medicines also have got momentum to overcome multi-resistance and antibiotics void.","PeriodicalId":49032,"journal":{"name":"Journal of Medical Imaging and Health Informatics","volume":"13 6","pages":"1-13"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2157-7420.1000328","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Imaging and Health Informatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2157-7420.1000328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

TB is a deadly disease and MDR-TB is spreading even DOTS drug regime has rigorously maintained with at least ten new drugs like isoniazid, capreomycin, dapsone, linezolid, pyrazinamide, ethambutol and Beda quinolone apart from traditional drugs like rifampicin, streptomycin, amikacin and clarithromycin. Rifampicin inhibits RNA polymerase and mutations in rpo gene codons give resistance. Streptomycin inhibits protein synthesis and mutation of ribosomal proteins and rRNA genes give resistance but no strAB or mphA1-9 mdr genes reported in Mycobacterium. Bedaquiline kills M. tuberculosis by inhibition of the membrane-bound F1F0-ATP synthase complex. Ciprofloxacin and ofloxacin were replaced by moxifloxacin that binds to DNA gyrase inhibiting DNA replication and/or transcription and mutations of gyrA at position 90 and 94 and gyrB at position 74, 88 and 91 give resistance. Kanamycin and amikacin inhibit protein synthesis and mutation of rrs gene gives resistance. However, aac2’-Ic type acetylating enzymes have also been suggested for multi-resistance. Ethambutol interferes with the biosynthesis of arabinogalactan in the cell wall and embB gene mutation at position 306 gives resistance. ErmMT methyl transferase adds methyl group to 23S rRNA at A2058 giving resistance to azithromycin and clarithromycin where capreomycin or viomycin peptide antibiotics may be effective drug. Ethionamide is a derivative of isonicotinic acid inhibits mycolic acid synthesis disrupting membrane function. Ethionamide resistance were linked due to mutations in etaA, ethA, ethR and inhA genes. Isoniazid is also a pro-drug and katG gene (S315T) mutation was reported for its resistance. Pyrazinamide after conversion to pyrazinoic acid disrupts membrane function inhibiting ATP synthesis and pncA or rpsA gene mutation likely gives resistance. Cycloserine is a peptidoglycan synthesis inhibitor competing D-Alanine ligase. We find beta-lactamase (BlaC) and penicillin binding protein (penA) as well as well studied emrB and qacB drug efflux proteins by genome wide search. But no 50-500 kb MDR plasmid carrying five or more mdr genes as found in most Enterobacteriaceae, have not sequenced in M. tuberculosis. We conclude that search for Mycobacterium plasmids must be accelerated pointing multi-resistance. Surely, phage therapy and gene medicines also have got momentum to overcome multi-resistance and antibiotics void.
结核分枝杆菌多重耐药现状及异常机制
结核病是一种致命的疾病,耐多药结核病正在蔓延,即使直接督导下的短程化疗也严格维持了至少十种新药,如异烟肼、自旋霉素、氨苯砜、利奈唑胺、吡嗪酰胺、乙胺丁醇和贝达喹诺酮,除了利福平、链霉素、阿米卡星和克拉霉素等传统药物。利福平抑制RNA聚合酶,rpo基因密码子突变产生耐药性。链霉素抑制蛋白合成,核糖体蛋白和rRNA基因突变产生耐药,但未见strAB或mphA1-9 mdr基因的报道。贝达喹啉通过抑制膜结合的F1F0-ATP合成酶复合物杀死结核分枝杆菌。用莫西沙星代替环丙沙星和氧氟沙星,莫西沙星与DNA回转酶结合,抑制DNA复制和/或转录,90和94位的gyrA和74、88和91位的gyrB突变产生耐药性。卡那霉素和阿米卡星抑制蛋白质合成,rrs基因突变产生耐药性。然而,aac2 ' -Ic型乙酰化酶也被认为具有多重抗性。乙胺丁醇干扰细胞壁中阿拉伯半乳聚糖的生物合成,embB基因306位突变产生耐药性。ErmMT甲基转移酶在A2058位点将甲基添加到23S rRNA上,使其对阿奇霉素和克拉霉素产生耐药性,其中卷曲霉素或维霉素肽抗生素可能是有效药物。乙硫酰胺是异烟酸的衍生物,抑制霉菌酸合成,破坏膜功能。由于etaA, ethA, ethR和inhA基因的突变,对乙硫酰胺的抗性被联系起来。异烟肼也是一种前药,据报道katG基因(S315T)突变导致其耐药。吡嗪酰胺转化为吡嗪酸后破坏膜功能,抑制ATP合成,pncA或rpsA基因突变可能产生耐药性。环丝氨酸是一种肽聚糖合成抑制剂,与d -丙氨酸连接酶竞争。通过全基因组搜索,我们发现了β -内酰胺酶(BlaC)和青霉素结合蛋白(penA),并研究了emrB和qacB药物外排蛋白。但是在大多数肠杆菌科中发现的携带5个或更多耐多药基因的50- 500kb的MDR质粒尚未在结核分枝杆菌中测序。我们认为,分枝杆菌质粒的寻找必须加快指向多重耐药。当然,噬菌体治疗和基因药物也有克服多重耐药和抗生素空白的势头。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medical Imaging and Health Informatics
Journal of Medical Imaging and Health Informatics MATHEMATICAL & COMPUTATIONAL BIOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Journal of Medical Imaging and Health Informatics (JMIHI) is a medium to disseminate novel experimental and theoretical research results in the field of biomedicine, biology, clinical, rehabilitation engineering, medical image processing, bio-computing, D2H2, and other health related areas. As an example, the Distributed Diagnosis and Home Healthcare (D2H2) aims to improve the quality of patient care and patient wellness by transforming the delivery of healthcare from a central, hospital-based system to one that is more distributed and home-based. Different medical imaging modalities used for extraction of information from MRI, CT, ultrasound, X-ray, thermal, molecular and fusion of its techniques is the focus of this journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信